Abstract
Rifaximin is an oral antimicrobial, intestine-selective, with low level of selection for resistant bacterial mutations and not systemic with adverse effects compared to placebo. It is used for the treatment of hepatic encephalopathy, travelers' diarrhea, irritable bowel syndrome, Clostridium difficile, ulcerative colitis and acute diarrhea. On the market rifaximin tablets of 200 mg under …